Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam to Prevent Post-Traumatic Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute head injury associated with one of the following:~Intracranial hemorrhage, including epidural, subdural and intracerebral hemorrhage or with cerebral contusion(s) of any size; Penetrating (foreign body) head injury; Skull fracture and dural tear; Seizure within 8 hours of head injury~* Onset of head injury within 8-hours of proposed treatment initiation.~* Glasgow Coma Scale 6-15.~Exclusion Criteria:~* Clinical contraindications:~  * Previous epilepsy or status epilepticus.~ * Any systemic illness or unstable medical condition that might pose additional risk, including: renal insufficiency, other unstable metabolic or endocrine disturbances, and active systemic cancer.~ * Psychosis within six months of enrollment as determined by history of hospitalization for psychosis or medications for psychosis.~ * Moderate to severe mental retardation (IQ\< 55 or\>2 school grade levels below the expected for age \[expected age = grade level +5\]).~* Clinical/Laboratory Indicators:~  * Serum creatinine \> 1.5 on the day of treatment initiation for adults.~ * Serum creatinine ≥1.5 for subjects ≥17 years old, ≥1.0 for subjects 13-17 years old and ≥0.7 for subjects 6-12 years old.~ * Pregnancy~ * Use of any CNS-active investigational drugs within 3 months of enrollment.~ * Use of Antiepileptic Drugs (AEDs) within two months of enrollment, for any indication.~ * Allergy/sensitivity to study drugs or their formulations:~ * Active drug or alcohol dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements:~ * Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: ACTIVE_COMPARATOR): 66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
- No Intervention Control (Type: NO_INTERVENTION): 60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).